問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Dermatology

更新時間：2023-09-19

劉洋豪Liu, Donald
  • Co-Principal Investigator
  • Clinical Trial Experience (year) -8 years -3 個月

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉洋豪

List

7Cases

2025-11-03 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2026-05-01 - 2027-12-31

Phase II

Active
A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat

  • Condition/Disease

    Subcutaneous Fat

  • Test Drug

    CBL-514

Participate Sites
8Sites

Recruiting8Sites

2023-04-01 - 2031-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2026-04-01 - 2027-03-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-01-09 - 2026-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-02-01 - 2024-08-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2019-05-01 - 2021-08-26

Phase II/III

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

  • Condition/Disease

    Alopecia Areata (AA)

  • Test Drug

    PF-06651600

Participate Sites
6Sites

Recruiting6Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB